Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/sofosbuvir Retreatment in HCV/HIV Co-infection
NCT02605304Phase 2Terminated
- Start
- Feb 2016
- Primary completion
- Jan 2017
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Harvoni in hepatitis C (HCV) (2 arms). Primary endpoints: Sustained Virologic Response at 12 Weeks After Treatment Discontinuation and Percentage of Participants With Grade 3 or Higher Adverse Event, Serious AE, or Discontinuation due to AE. Started Feb 2016; status: terminated.
02
Drugs
Harvoni
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02605304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605304.